• Earlier this month, Eli Lilly announced positive topline Phase 3 results for orforglipron, its investigational oral weight management therapy, and reported strong second quarter earnings with sales reaching US$15.56 billion and net income of US$5.66 billion.
• Senderra Specialty Pharmacy separately revealed that it has added Lilly’s EBGLYSS treatment for atopic dermatitis to its SenderraCare+ digital platform, potentially enhancing patient access and adherence for this specialty medication.
• We’ll examine how robust clinical data for orforglipron and improved financial guidance could reshape Eli Lilly’s long-term growth outlook.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Eli Lilly Investment Narrative Recap

Being a shareholder in Eli Lilly means believing in the company’s ability to turn innovation into growth, especially through high-impact clinical data and execution on new product launches. The latest positive topline results from the Phase 3 orforglipron trial could support the company’s ambitions in obesity and weight management, a key near-term catalyst, while pricing pressures in the U.S. for core products like Mounjaro remain the most significant risk. Based on recent news, the impact on this risk/catalyst dynamic appears limited for now.

One recent announcement, the integration of Lilly’s EBGLYSS treatment for atopic dermatitis into Senderra’s digital platform, highlights the company’s commitment to expanding patient access and medication adherence in specialty care. This initiative complements the broader catalyst of pipeline innovation, supporting the goal of sustainable revenue growth in high-demand therapeutic areas.

However, it is important for investors to recognize that in contrast to product breakthroughs, ongoing pricing pressure in the U.S. market might affect expected revenue...

Eli Lilly's narrative projects $86.4 billion revenue and $32.2 billion earnings by 2028. This requires 20.8% yearly revenue growth and a $21.1 billion earnings increase from $11.1 billion today.

Uncover how Eli Lilly's forecasts yield a $956.67 fair value, a 50% upside to its current price.

Exploring Other Perspectives

Twenty-five different fair value estimates from the Simply Wall St Community range widely from US$650 to US$1,250 per share. While the obesity pipeline stands out as a growth driver, persistent pricing risk could shape results for years to come, so consider multiple viewpoints.

Explore 25 other fair value estimates on Eli Lilly - why the stock might be worth as much as 96% more than the current price!

Build Your Own Eli Lilly Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Eli Lilly research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.